Physician profile
Miranda R Hernly
NPI 1831815216
$4,153.14
in general payments reported to CMS, 2019-2025
25 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $229 · 2023: $1,158 · 2024: $1,397 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,924.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.00 | 2023-2025 | |
| Alkermes, INC. | $478.54 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Viiv Healthcare Company | $379.71 | 2022-2025 | Dovato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.38 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.23 | 2022-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $280.31 | 2022-2025 | |
| Novo Nordisk INC | $249.44 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $158.39 | 2022-2025 | Trintellix |
| Lilly USA, LLC | $152.21 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Otsuka America Pharmaceutical, INC. | $151.21 | 2023-2025 | Rexulti |
| Gilead Sciences, INC. | $106.16 | 2023-2025 | Epclusa |
| Corcept Therapeutics | $76.20 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.49 | 2024 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $56.41 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $51.45 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $47.25 | 2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $37.46 | 2023-2025 | Quviviq, Quviviq |
| Lundbeck LLC | $37.23 | 2025 | Abilify Asimtufii, Rexulti |
| Novartis Pharmaceuticals Corporation | $35.76 | 2023 | |
| Astellas Pharma US INC | $32.91 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $32.08 | 2022-2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $27.95 | 2025 | Fanapt |
| Medtronic, INC. | $23.36 | 2023 | Minimed 780g |
| Amgen INC. | $20.29 | 2024 | Otezla, Repatha |
| Ironshore Pharmaceuticals INC. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Hernly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.